{"groups":[{"description":"Patients will receive INCMGA00012 500 mg by intravenous infusion on Day1 of each cycle.\n\nRetifanlimab: INCMGA00012 500 mg will be administered on Day1 of each cycle (once every four weeks), for up to 2 years.","id":"FG000","title":"Interventional Arm"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"16"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Lost to Follow-up"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"18"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"18"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Male patients ≥ 18 years of age. ECOG Performance Status ≤ 1. Life expectancy ≥12 weeks. Histologically-proven PSqCC. Locally advanced unresectable/metastatic stage 4 PSqCC that is not amenable to resection with curative intent (T4 or N3 or M1). - Radiological evidence of locally advanced or metastatic disease. - Adequate organ function.","recruitmentDetails":"Between April 2020 and August 2021, a total of 18 male patients with locally advanced unresectable or metastatic PSqCC stage 4 (i.e. T4 or N3 or M1)presenting radiologic PD and/or chemotherapy were enrolled at 9 sites. Due there's only one arm, all the patients received INCMGA00012 until disease progression, death or discontinuation from the study."}